The stock may react positively to the promising early clinical data in two high-value therapeutic areas (oncology and obesity), but the significant increase in losses and share count (up 44% YoY) could pressure valuation. Monitor upcoming mid-2026 data readouts for CRB-701 and CRB-913 as key catalysts.
Price Chart
Executive Summary
Corbus Pharmaceuticals reported Q4 and full-year 2025 financial results with a wider net loss of $20.6M ($1.25/share) compared to $9.5M ($0.78/share) in the prior year, driven by higher R&D expenses. The company highlighted positive early-stage clinical data for CRB-701 in cancer and CRB-913 in obesity, and completed a $75M public offering, extending its cash runway into 2028.
Key Financial Metrics
Key Facts
- Net loss for Q4 2025 was $20.6M vs. $9.5M in Q4 2024; full-year loss was $78.5M vs. $40.2M in 2024.
- R&D expenses nearly doubled to $18.4M in Q4 2025 from $8.8M in Q4 2024.
- Cash, cash equivalents, and investments totaled $163.3M as of December 31, 2025, up from $149.1M in 2024.
- Completed $75M public offering in Q4 2025, funding operations into 2028.
- CRB-701 showed unconfirmed ORR of 47.6% in HNSCC and 37.5% in cervical cancer at 3.6 mg/kg dose.
- CRB-913 achieved 2.9% placebo-adjusted weight loss in 14 days with favorable GI safety profile.
- CRB-601 program deprioritized after Phase 1 completion.
Financial Impact
Increased R&D spend by $9.4M YoY; cash position increased by $14.2M net of losses; $75M gross proceeds from offering.
Risk Factors
- Clinical programs are early-stage; mid-2026 data may not confirm initial efficacy signals.
- Significant dilution from recent offering and increased share count.
- CRB-601 program deprioritized, narrowing pipeline diversification.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251723 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 8-K | $4.33 | awaiting T+60 | — | $4.05 (−6.47%) |
Sep 30, 2026 26d ago | SC 13G | $6.34 | awaiting T+60 | — | $4.05 (−36.12%) |
Sep 22, 2026 4w ago | Institutional Cluster | $7.88 | awaiting T+60 | — | $4.05 (−48.57%) |
Sep 14, 2026 6w ago | 8-K | $8.08 | awaiting T+60 | — | $4.05 (−49.88%) |
Sep 11, 2026 6w ago | Press Release | $8.08 | awaiting T+60 | — | $4.05 (−49.88%) |
Aug 12, 2026 10w ago | Insider Cluster | $10.08 | awaiting T+60 | — | $4.05 (−59.82%) |
Aug 10, 2026 11w ago | Insider Cluster | $9.51 | awaiting T+60 | — | $4.05 (−57.41%) |
May 26, 2026 21w ago | 8-K | $7.91 $9.99 | ▲ +26.30% | ▲ +23.57% | $4.05 (−48.80%) |
May 21, 2026 22w ago | 8-K | $11.51 $10.49 | ▼ −8.86% | ▼ −13.16% | $4.05 (−64.81%) |
May 14, 2026 23w ago | 8-K | $11.98 $9.46 | ▼ −21.04% | ▼ −24.62% | $4.05 (−66.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers